Cancer News and Research

Latest Cancer News and Research

IGR, IPSEN sign 3 year medical oncology agreement

IPSEN, a global biopharmaceutical company represented by Claude Bertrand, Executive Vice President, R&D and Chief Scientific Officer, and Institut de cancérologie Gustave Roussy, a leading international cancer center represented by Professor Alexander Eggermont, General Director, today announced the signature of a partnership in the area of medical oncology to leverage the combined expertises of their respective R&D teams.

12 Jul 2011

AACR Conference on Frontiers in Basic Cancer Research to be held in San Francisco

For more than 100 years, the American Association for Cancer Research has been the premier leader in the basic science of cancer research.

12 Jul 2011

Hutchinson Center receives $20M NIH grant to eradicate HIV infection

Whether a stem cell transplant using an HIV-infected person's own genetically modified immune cells can become a cure for the disease is the focus of a new $20 million, five-year research grant award announced today by the National Institutes of Health to Fred Hutchinson Cancer Research Center.

12 Jul 2011

Maternal smoking during pregnancy causes serious birth defects

To dispel any uncertainty about the serious harm caused by smoking to babies and pregnant women, the first-ever comprehensive systematic review of all studies over the past 50 years has established clearly that maternal smoking causes a range of serious birth defects including heart defects, missing/deformed limbs, clubfoot, gastrointestinal disorders, and facial disorders.

12 Jul 2011

Cancer Cell publishes Epizyme and collaborators' breakthrough research on MLL

Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer and rare disease patients, and its collaborators announced the publication in Cancer Cell of breakthrough research in the treatment of MLL-rearranged leukemia (MLL), a genetically-defined subset of acute lymphoblastic leukemia and acute myelogenous leukemia.

12 Jul 2011

Sunshine completes Adva-27a study in Multidrug Resistant Breast Cancer cell line

Sunshine Biopharma Inc., a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line.

12 Jul 2011

American Red Cross issues appeal for donors to address critical blood shortage

The American Red Cross today issued an appeal for blood donors to roll up a sleeve and address a critical shortage across the nation.

12 Jul 2011

Specific miRNAs play a key role in melanoma metastasis

Researchers at the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, identified for the first time the key role specific microRNAs play in melanoma metastasis to simultaneously cause cancer cells to invade and immunosuppress the human body's ability to fight abnormal cells.

12 Jul 2011

Study: 82% of Georgia hospitals do not offer palliative care services

Hospitals across the nation are increasingly implementing palliative care programs to help patients manage the physical and emotional burdens of serious illnesses, but a new University of Georgia study finds that 82 percent of the state's hospitals do not offer palliative care services.

12 Jul 2011

BioAlliance receives European patent for Livatag to treat primary liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces the grant of a European patent protecting its Transdrug nanotechnology.

12 Jul 2011

Researchers identify obesity-related paradoxes among Chinese youth

Teenaged boys from well-off Chinese families who say they are physically active and eat plenty of vegetables but few sweets are more likely to be overweight, according to a study led by researchers at the Keck School of Medicine of the University of Southern California.

12 Jul 2011

Enrollment complete in Advaxis ADXS-HPV Phase II CIN study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed enrollment of the first 40 subject cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

12 Jul 2011

People with long term debilitating physical illness demonstrate mental resilience

People who have a long term debilitating physical illness demonstrate mental resilience according to Understanding Society, the world's largest longitudinal household study. The first findings reveal that people diagnosed with cancer, diabetes, respiratory or cardiovascular disease report similar mental health scores to those without physical illness.

11 Jul 2011

NIAID awards $14 million a year for new HIV research

Three research teams focused on developing strategies that could help to rid the body of HIV are receiving grants totaling more than $14 million a year, for up to five years, the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health announced today.

11 Jul 2011

New method allows for concurrent treatment of spinal tumors and stabilization of the spine

The Orthopedic Clinic and Policlinic at the University Medical Center of Johannes Gutenberg University Mainz has recently deployed a new system for the treatment of spinal tumors for the first time.

11 Jul 2011

CMC hospital Ludhiana upgrades to MLCi2-equipped Elekta Compact linear accelerator

Christian Medical College & Hospital (CMC) Ludhiana is the site of the first Elekta Compact™ linear accelerator in the world to be field-upgraded to an MLCi2-equipped Elekta Compact, completing the transformation in less than a week. MLCi2 shapes treatment beams, enabling doctors to provide more accurate delivery to the target, while limiting radiation exposure to surrounding structures.

From Elekta 11 Jul 2011

Cancer Research UK awards £12 million to 10 exceptional researchers

Cancer Research UK has given a number of prestigious grants to new investigators who are set to become the eminent cancer scientists of the future.

11 Jul 2011

Anavex exercises warrants to raise $1.575 million

Anavex Life Sciences Corp. is pleased to announce that it has raised $1,575,000 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73, the company's lead drug candidate for Alzheimer's disease, to advance other compounds in the Anavex pipeline, and for general corporate purposes.

11 Jul 2011

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland, announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.

11 Jul 2011

Generex announces convertible preferred stock securities purchase agreement

Generex Biotechnology Corporation today announced that it entered into a securities purchase agreement with certain institutional investors on July 8, 2011.

11 Jul 2011